BioXcel Therapeutics Inc. (BTAI)
BioXcel Therapeutics Statistics
Share Statistics
BioXcel Therapeutics has 5.49M shares outstanding. The number of shares has increased by 39.15% in one year.
| Shares Outstanding | 5.49M |
| Shares Change (YoY) | 39.15% |
| Shares Change (QoQ) | 5.23% |
| Owned by Institutions (%) | 1.26% |
| Shares Floating | 4.56M |
| Failed to Deliver (FTD) Shares | 1.97K |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 347.08K, so 0.7% of the outstanding shares have been sold short.
| Short Interest | 347.08K |
| Short % of Shares Out | 0.7% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -0.3. BioXcel Therapeutics's PEG ratio is 0.
| PE Ratio | -0.25 |
| Forward PE | -0.3 |
| PS Ratio | 6.69 |
| Forward PS | 0 |
| PB Ratio | -0.16 |
| P/FCF Ratio | -0.21 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioXcel Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of -1.11.
| Current Ratio | 1.68 |
| Quick Ratio | 1.65 |
| Debt / Equity | -1.11 |
| Debt / EBITDA | -2.33 |
| Debt / FCF | -1.43 |
| Interest Coverage | -4.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $61.24K |
| Profits Per Employee | $-1.61M |
| Employee Count | 37 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -96.19% in the last 52 weeks. The beta is 0.64, so BioXcel Therapeutics's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -96.19% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 8.91 |
| Relative Strength Index (RSI) | 34.55 |
| Average Volume (20 Days) | 4.65M |
Income Statement
In the last 12 months, BioXcel Therapeutics had revenue of 2.27M and earned -59.6M in profits. Earnings per share was -23.51.
| Revenue | 2.27M |
| Gross Profit | 2.27M |
| Operating Income | -67.25M |
| Net Income | -59.6M |
| EBITDA | -44.16M |
| EBIT | -44.47M |
| Earnings Per Share (EPS) | -23.51 |
Balance Sheet
The company has 29.85M in cash and 102.95M in debt, giving a net cash position of -73.09M.
| Cash & Cash Equivalents | 29.85M |
| Total Debt | 102.95M |
| Net Cash | -73.09M |
| Retained Earnings | -650.2M |
| Total Assets | 38.34M |
| Working Capital | 15.16M |
Cash Flow
In the last 12 months, operating cash flow was -72.03M and capital expenditures 0, giving a free cash flow of -72.03M.
| Operating Cash Flow | -72.03M |
| Capital Expenditures | 0 |
| Free Cash Flow | -72.03M |
| FCF Per Share | -28.41 |
Margins
Gross margin is 100%, with operating and profit margins of -2967.56% and -2630.14%.
| Gross Margin | 100% |
| Operating Margin | -2967.56% |
| Pretax Margin | -2630.14% |
| Profit Margin | -2630.14% |
| EBITDA Margin | -1948.85% |
| EBIT Margin | -2967.56% |
| FCF Margin | -3178.6% |
Dividends & Yields
BTAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BTAI is $48, which is 2863% higher than the current price. The consensus rating is "Buy".
| Price Target | $48 |
| Price Target Difference | 2863% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Feb 10, 2025. It was a backward split with a ratio of 1:16.
| Last Split Date | Feb 10, 2025 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | -26.99 |
| Piotroski F-Score | 2 |